April 2014
Volume 55, Issue 13
ARVO Annual Meeting Abstract  |   April 2014
Antibacterial Susceptibility of Coagulase Negative Staph Before and After Prophylactic Use of Besifloxacin and Moxifloxacin
Author Affiliations & Notes
  • Frank A Bucci
    Bucci Laser Vision Institute, Wilkes-Barre, PA
  • Christine M Sanfilippo
    Microbiology and Sterilization Sciences, Bausch & Lomb Incorporated, Rochester, NY
  • Heleen H DeCory
    Medical Affairs, Bausch & Lomb Incorporated, Rochester, NY
  • Loretta Amico
    Bucci Laser Vision Institute, Wilkes-Barre, PA
  • Ruth E Evans
    Bucci Laser Vision Institute, Wilkes-Barre, PA
  • Timothy L Comstock
    Medical Affairs, Bausch & Lomb Incorporated, Rochester, NY
  • Footnotes
    Commercial Relationships Frank Bucci, Bausch & Lomb Incorporated (C), Bausch & Lomb Incorporated (F); Christine Sanfilippo, Bausch & Lomb Incorporated (E); Heleen DeCory, Bausch & Lomb Incorporated (E); Loretta Amico, None; Ruth Evans, None; Timothy Comstock, Bausch & Lomb Incorporated (E)
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science April 2014, Vol.55, 1489. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Frank A Bucci, Christine M Sanfilippo, Heleen H DeCory, Loretta Amico, Ruth E Evans, Timothy L Comstock; Antibacterial Susceptibility of Coagulase Negative Staph Before and After Prophylactic Use of Besifloxacin and Moxifloxacin. Invest. Ophthalmol. Vis. Sci. 2014;55(13):1489.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

We previously reported that prophylactic use of besifloxacin 0.6% (BESI) or moxifloxacin 0.5% (MOXI) QID for 3 days led to significant reductions in lid CFUs of commensal bacteria, but only BESI produced significant reductions in lid CFUs 1 hr after a single treatment. BESI also led to more rapid and significant elimination of methicillin resistant (MR) Staphylococcus epidermidis. Here we report in vitro susceptibilities to BESI and comparator antibacterials of commensal coagulase negative staphylococci (CoNS) from this study before and after treatment.


Patients were randomized to BESI or MOXI QID for 3 days prior to cataract surgery in their surgical eye, and 1 hr prior to a final culture in their non-surgical eye, on the day of surgery. Lid and conjunctival cultures were obtained from both eyes before (V1) and after treatment (V2). Samples were submitted to a central laboratory for enumeration, species identification, and susceptibility testing. Minimum inhibitory concentrations (MICs) were determined by broth microdilution for a panel of comparator antibacterials including BESI and MOXI.


Data from 63 patients were analyzed. Prior to treatment, the predominant bacteria on both conjunctiva and lids were CoNS. BESI had the lowest MIC90 against CoNS (0.5 µg/mL), lower than that of vancomycin (2 µg/mL). Against MR-CoNS, the MIC90 of BESI was 8- to 64-fold lower than that of other fluoroquinolones (MOXI, gatifloxacin, levofloxacin, ciprofloxcin). Fewer BESI-treated eyes harbored CoNS at V2 compared to MOXI-treated eyes, with a significant difference between treatments for lids (P<0.05). In BESI-treated eyes, nearly all V2 isolates were either a new colonizing CoNS not present at V1 or the V1 CoNS species present at reduced CFUs. In several MOXI-treated eyes, the V2 CoNS was the same species as the V1 isolate at unchanged or increased CFUs—in many of these cases (n=11 isolates, 8 patients) the isolate had an MIC predictive of intermediate/full resistance to MOXI.


BESI demonstrated the strongest in vitro potency against commensal CoNS in this study and was more effective than MOXI in decreasing the bacterial load on the lids and conjunctiva. Several MOXI-treated eyes had unchanged or increased bacterial loads attributable to the presence of MOXI-resistant CoNS.

Keywords: 433 bacterial disease • 422 antibiotics/antifungals/antiparasitics • 466 clinical (human) or epidemiologic studies: treatment/prevention assessment/controlled clinical trials  

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.